Immune Modulation by Exosomes in COVID-19

Last updated: January 16, 2024
Sponsor: University of Ulm
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scar Tissue

Cystic Fibrosis

Pulmonary Fibrosis

Treatment

Application of exosomes in a whole blood assay

Clinical Study ID

NCT05191381
Lung fibrosis in COVID19
  • Ages 18-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Critically ill COVID-19 patients with lung dysfunction
  • COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
  • Body weight > 50 kg
  • Informed consent

Exclusion

Exclusion Criteria:

  • Pregnant or breast feeding women

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Application of exosomes in a whole blood assay
Phase:
Study Start date:
December 22, 2021
Estimated Completion Date:
December 31, 2026

Study Description

Critically ill patients with COVID-19 may develop lung failure and require extracorporal oxygenation due to hyperinflammation and progressive lung fibrosis. The anti-inflammatory and immune modulatory function of mesenchymal stem cells will be investigated by whole blood stimulation experiments using stem cell derived exosomes. Exosome preparations have been characterized by miRNA and protein expression patterns and suggest their tissue regenerative capacity.

The hypothesis of the present study is that mesenchymal stem cell derived exosomes attenuate inflammation and support anti-fibrotic pathways.

Connect with a study center

  • Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine

    Ulm, 89070
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.